Key Takeaways
- Immutep shares skyrocketed more than 101% following the announcement that eftilagimod alfa (efti) secured FDA Orphan Drug Designation.
- The designation applies to soft tissue sarcoma treatment, a rare malignancy impacting under 200,000 Americans annually.
- Immutep gains access to significant advantages including seven-year marketing exclusivity, tax incentives, waived fees, and enhanced FDA guidance.
- The regulatory approval stems from encouraging Phase II EFTISARC-NEO clinical trial results that successfully achieved its primary efficacy goal across 38 participants.
- This development arrives on the heels of discontinuing the TACTI-004 Phase III study, a move projected to extend the company’s financial resources past Q2 2027.
Shares of Immutep experienced a remarkable surge this Wednesday after the Australian biotechnology firm secured Orphan Drug Designation (ODD) from the United States Food and Drug Administration for eftilagimod alfa, its flagship oncology candidate.
The Australia-based biotech company witnessed its shares rocket 101.3% to reach A$0.079 throughout Wednesday’s trading session.
The regulatory designation specifically addresses efti’s application in treating soft tissue sarcoma (STS), an uncommon malignancy representing a significant area of unmet clinical necessity within the American healthcare landscape.
Receiving Orphan Drug Designation delivers substantial commercial and regulatory advantages: specialized FDA consultation, possible tax relief opportunities, exemption from certain regulatory fees, and critically, seven years of exclusive marketing rights upon eventual product approval.
The regulatory authority’s determination relied on compelling evidence derived from the Phase II EFTISARC-NEO clinical investigation. This study evaluated efti when administered alongside radiotherapy and Merck’s KEYTRUDA (pembrolizumab) in patients diagnosed with operable soft tissue sarcoma before undergoing surgical intervention.
Among 38 patients assessed for efficacy, the clinical trial successfully achieved its predetermined primary outcome measure. Researchers documented a median tumour hyalinization/fibrosis rate reaching 51.5%, substantially surpassing the established threshold of 35% and dramatically exceeding the historical standard of approximately 15% typically observed with radiotherapy monotherapy.
The treatment demonstrated consistent efficacy across various sarcoma subtypes. Researchers characterized the safety data as encouraging, noting that no patients experienced surgical delays due to treatment-related complications.
TACTI-004 Trial Discontinuation
This encouraging regulatory milestone follows closely after Immutep’s decision in early March to discontinue its TACTI-004 Phase III clinical investigation. That particular study was evaluating efti as a first-line therapeutic option for non-small cell lung cancer patients.
An Independent Data Monitoring Committee issued a recommendation to terminate the trial based on futility analysis. The organization is currently implementing an orderly shutdown of TACTI-004 operations.
Immutep indicated that discontinuing the trial should significantly extend its financial runway, pushing operational capacity well beyond the previously projected Q2 2027 timeframe.
Development Portfolio and Financial Position
Beyond its soft tissue sarcoma and lung cancer programs, Immutep maintains five distinct LAG-3-focused development programs. Among these initiatives, IMP761 is currently undergoing Phase I clinical evaluation targeting autoimmune disease indications.
The organization reported a net operating loss of A$61.4 million during the 2025 fiscal period, representing an increase from the A$42.7 million loss recorded in fiscal 2024.
As a pre-revenue biotechnology enterprise, Immutep continues requiring supplemental capital infusions to maintain its ongoing research and development operations.
The company sustains strategic collaborations with leading pharmaceutical corporations, including Merck (MSD), to facilitate advancement of its therapeutic pipeline.
The EFTISARC-NEO clinical trial data, which directly underpinned Wednesday’s FDA orphan designation, incorporated translational research findings aligned with efti’s proposed biological mechanism — immune system activation through LAG-3 pathway modulation.
